12-Month Intraocular Pressure and Hypotensive Medications Outcomes After Phaco-ELIOS Procedure-A Real World Study.

PRÉCIS: Combined phaco-ELIOS in ocular hypertension and glaucoma showed a statistically significant reduction in the number of hypotensive medications of 1.5 compared with baseline, with 78.4% of eyes being medication-free at 12 months.

PURPOSE: To describe the change in medication and intraocular pressure 12 months after the combined phacoemulsification-ELIOS procedure.

METHODS

Retrospective, multicenter interventional case series of adults with ocular hypertension or glaucoma undergoing phaco-ELIOS. Clinical data were collected and analyzed from preoperative baseline up to 12 months postoperatively. The primary outcome was the mean change in medication compared with baseline. Secondary outcomes were intraocular pressure change from baseline, incidence of acute postoperative intraocular pressure elevation, and surgical success at 1 year, defined as intraocular pressure reduction of ≥20% compared with baseline with no increase in medications, or reduction of ≥1 medications compared with baseline with intraocular pressure equal or below baseline, with no secondary glaucoma surgeries and no loss of light perception.

RESULTS

One hundred twelve eyes were included. Forty-two patients (51.2%) were female. Mean (±SD) age was 70.6 (±9.6) years. The most frequent diagnosis was primary open angle glaucoma (71.4%). The mean number of medications at baseline and 12 months was 1.8 (±0.8) and 0.4 (±0.7), respectively, representing a reduction of 1.5 (±1.0) ( P <0.0001). At the end of follow-up, 78.4% of eyes were medication-free. Mean intraocular pressure at baseline and 12 months was 19.9 (±4.0) mm Hg and 16.7 (±2.6) mm Hg, respectively, a significant decrease of 3.2 mm Hg (±4.0) or 13.7% ( P <0.0001). Surgical success was achieved in 75.9% of eyes at 12 months.

CONCLUSIONS

Combined phaco-ELIOS in glaucoma significantly reduced medication use and IOP, with over 75% of eyes being medication-free at 12 months.